
# PHARMACEUTICAL 2019

# **XOMA Corp** Rank 124 of 371







### PHARMACEUTICAL 2019

## XOMA Corp Rank 124 of 371



The relative strengths and weaknesses of XOMA Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of XOMA Corp compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 94% points. The greatest weakness of XOMA Corp is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 53% points.

The company's Economic Capital Ratio, given in the ranking table, is -62%, being 270% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	47,626
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,703
Liabilities, Non-Current	22,280
Other Assets	16,100
Other Compr. Net Income	0
Other Expenses	2,735
Other Liabilities	17,017
Other Net Income	4,338
Property and Equipment	59
Research and Development	1,682
Revenues	5,299
Selling, General and Administrative Expense	18,563

Output Variable	Value in 1000 USD
Assets	63,785
Liabilities	45,000
Expenses	22,980
Stockholders Equity	18,785
Net Income	-13,343
Comprehensive Net Income	-13,343
Economic Capital Ratio	-62%